losartan has been researched along with Growth Disorders in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Growth Disorders: Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension." | 7.83 | Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension. ( Morgan, DA; Peotta, V; Pitz, KM; Rahmouni, K; Rice, OM; Roghair, RD; Segar, JL, 2016) |
| "Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension." | 3.83 | Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension. ( Morgan, DA; Peotta, V; Pitz, KM; Rahmouni, K; Rice, OM; Roghair, RD; Segar, JL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cappuccio, G | 1 |
| Caiazza, M | 1 |
| Roca, A | 1 |
| Melis, D | 2 |
| Iuliano, A | 1 |
| Matyas, G | 1 |
| Rubino, M | 1 |
| Limongelli, G | 1 |
| Brunetti-Pierri, N | 2 |
| Piccolo, P | 1 |
| Mithbaokar, P | 1 |
| Sabatino, V | 1 |
| Tolmie, J | 1 |
| Schiaffino, MC | 1 |
| Filocamo, M | 1 |
| Andria, G | 1 |
| Peotta, V | 1 |
| Rahmouni, K | 1 |
| Segar, JL | 1 |
| Morgan, DA | 1 |
| Pitz, KM | 1 |
| Rice, OM | 1 |
| Roghair, RD | 1 |
1 trial available for losartan and Growth Disorders
| Article | Year |
|---|---|
A pilot clinical trial with losartan in Myhre syndrome.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Child; Child, Preschool; Cryptorchidism; | 2021 |
2 other studies available for losartan and Growth Disorders
| Article | Year |
|---|---|
SMAD4 mutations causing Myhre syndrome result in disorganization of extracellular matrix improved by losartan.
Topics: Adolescent; Adult; Child; Cryptorchidism; Extracellular Matrix; Facies; Female; Fibroblasts; Growth | 2014 |
Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension.
Topics: Angiotensins; Animals; Blood Pressure; Disease Models, Animal; Growth Disorders; Hypertension; Lepti | 2016 |